Solid Tumors and Hematologic Malignancy
6
0
0
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
33.3%
2 terminated out of 6 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
A Dose-escalation Study in Subjects With Advanced Malignancies
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors